Factors associated with incidence of stroke and heart failure among people living with HIV in Ghana: Evaluating Vascular Event Risk while on Long-Term Antiretroviral Suppressive Therapy (EVERLAST) Study

Fred Stephen Sarfo MD, PhD, PhD1,2 | Betty Norman MD1,2 | Lambert Appiah MD1,2 | Bruce Ovbiagele MD, MSc3

Abstract
People living with HIV (PLWH) have a two-fold higher risk of cardiovascular diseases (CVDs) compared with HIV-negative populations. Although 70% of the global HIV population reside in Africa, data on CVD outcomes among PLWH are scarce. We seek to evaluate factors associated with incidence of stroke and heart failure in a prospective cohort of Ghanaian PLWH. We followed up a cohort of PLWH on antiretroviral therapy for 12 months to assess rates of clinically adjudicated stroke, and heart failure. We calculated incidence rates of events/1000 person-years and fitted Cox proportional hazards regression models to identify factors associated with incident stroke and heart failure as a combined outcome measure and as separate outcome measures. Among 255 participants, the mean age was 46 years and 211 (82.7%) were female. The participants contributed 245 years of follow-up data with mean follow-up duration of 11.5 months. There were three incident strokes giving an incidence rate of 12.24 per 1000 person-years (95% CI: 3.13–33.33) and two heart failure events with an incidence rate of 8.16 (95%CI: 1.37–26.97) per 1000 py. The combined event rate was 20.41 (95% CI: 7.48–45.24) per 1000 py. Being hypertensive was associated with aHR of 8.61 (1.32–56.04) of the combined outcome while each 100 cells/mm³ rise in CD4 count was associated with aHR of 0.56 (0.35–0.88). Carotid bulb intimal media thickness was independently associated with stroke occurrence with aHR of 12.23 (1.28–117.07). People living with HIV on long-term cART in this Ghanaian sample have high rates of clinically adjudicated cardiovascular diseases driven by uncontrolled hypertension and persisting immunosuppression. Integration of CVD care into routine HIV management may help alleviate this untoward confluence of rising CVDs among PLWH.

INTRODUCTION
People living with HIV (PLWH) have more than twice an increased risk of cardiovascular disease (CVDs) compared with HIV-negative populations.1,2 With a steady diminution in deaths attributable to opportunistic infections and malignancies due to widespread access to combination antiretroviral therapy, CVDs have now emerged as leading causes of mortality and morbidity among...
PLWH. Direct vascular inflammation, dyslipidemia, and insulin resistance are some of the mechanisms linking HIV with the development of both overt and covert CVDs. Global estimates based on a meta-analysis of 793,635 PLWH with a total of 3.5 million person-years gave a crude incidence rate of CVD per 1000 person-years of 6.18 (95%CI: 4.58–8.34). However, almost all the data on CVD events in HIV have been reported from cohorts in Europe, Northern America, Israel, and Asian countries. There were no data from sub-Saharan Africa (SSA) in this meta-analysis of 80 studies due to paucity of prospective studies evaluating CVD outcomes among PLWH. Sub-Saharan Africa harbors 70% of the 37 million individuals living with HIV on the globe and has concurrently witnessed an unprecedented rise in CVD burden over the last three decades. There are indications that a convergence of a steep rise in vascular risk factors such as hypertension, dyslipidemia, and obesity among a population of PLWH with heightened vascular inflammation may engender an increased incidence of CVD events. We have recently reported very high incidence rates of hypertension, pre-diabetes, and diabetes mellitus among PLWH in Ghana. Poor detection and control of major vascular risk factors which is rife in SSA may contribute to a higher burden of CVDs among PLWH. Furthermore, the relatively younger age of HIV patients, less frequent use of cigarette, female predominance, and less substance abuse among PLWH in SSA constitute a differential risk factor profile to those observed in high-income countries. We, therefore, sought in this study to assess the incidence rates of stroke and heart failure in a prospective cohort of Ghanaian PLWH.

2 METHODS

2.1 Study design & population

The Evaluation of Vascular Event Risk while on Long-term Anti-retroviral Suppressive Therapy (EVERLAST) Study is a case-control study to assess the prevalence of CVD risk among PLWH compared with HIV-negative controls. Ethical approval for the study was obtained from the Kwame Nkrumah University of Science and Technology Committee of Human Research Publications and Ethics. PLWH were included if they were ≥30 years and receiving cART for at least 1 year at the HIV clinic of the Komfo Anokye Teaching Hospital, a tertiary medical facility in Kumasi, Ghana. For the present analysis, we focus on 12-month prospective CVD outcomes (incident stroke, heart failure, and acute coronary disease) among PLWH on cART at enrollment. Although we enrolled PLWH who were cART naïve and HIV-negative controls in the EVERLAST study, their follow-up was less rigorous and has not been included in the present report. All participants provided written informed consent.

2.2 Study evaluations

Data on socio-demographic characteristics, namely age, sex, and location of residence (rural, peri-urban, and urban), were collected. Among the PLWH, we collected data through interview and review of medical record chart extraction on HIV disease characteristics, such as current CD4 cell count, HIV-1 viral load, and past and current history of cART. We assessed the traditional vascular risk factors using history-taking, physical examination, and by analyzing blood samples for HBA1c, fasting blood glucose, and lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides).

2.3 Prospective follow-up

People living with HIV on cART at enrollment were prospectively followed up for 12 months via clinic visits every 3 months. During the follow-up period, participants were assessed through use of clinical history and examination with diagnostic investigations were feasible for the presence of CVDs including incident stroke or heart failure. The following definitions were used for vascular risk factors and the study outcomes of interest:

- Hypertension: Blood pressure (BP; mean of three measurements) was taken on each study participant following a standard protocol. A cutoff of at least 140/90 mmHg according to WHO definitions or use of antihypertensive drugs was regarded as indicators of hypertension.
- Dyslipidemia was defined as a fasting total cholesterol concentration of ≥5.2 mmol/L, HDL cholesterol ≤1.03 mmol/L, LDL cholesterol ≥3.4 mmol/L, or serum triglyceride of ≥1.7 mmol/L, according to National Cholesterol Education Program guidelines.
- Obesity was defined using the WHO guidelines with a waist-to-hip ratio (WHR) cutoff of 0.90 (men) and 0.85 (women) or body mass index (BMI) of 30 kg/m² for obesity. WHR was used to assess burden of central adiposity, and BMI was used to further categorize participants into underweight, ideal weight, overweight, and obese.
- Diabetes mellitus was diagnosed based on self-report or HBA1c >6.5%.
- Carotid doppler assessments: The average intimal medial thickness (IMT) of the left and right common carotid arteries (CCA) obtained at three angles (anterior, lateral, and posterior bilaterally) at the optimum angle of insonation was reported as the overall CIMT for the CCA. We also measured IMT of the carotid bulb and internal carotid arteries.
- Stroke: Stroke diagnosis was based on the World Health Organization definition, if participant had ever experienced sudden onset of weakness or sensory loss on one side of the body, sudden loss of vision, or sudden loss of speech.
- Heart failure: Congestive heart failure was defined clinically as a history of dyspnea on minimal exertion, paroxysmal nocturnal dyspnea or acute pulmonary edema or the presence of distended neck veins (in other than the supine position and in the absence of venous obstruction), bilateral ankle edema (not caused by a
condition other than cardiac failure), hepatomegaly, crepitations in the absence of pulmonary disease, positive S_{2}, or chest radiographic evidence of pulmonary congestion (pleural fluid, pulmonary venous congestion, and prominent pulmonary veins) with or without cardiomegaly.

2.4 | Statistical analysis

Crude incidence rates of stroke or heart failure during follow-up were calculated and expressed as events/1000 person-years of follow-up (PYFU) and 95% CI calculated using the mid-P exact test. Comparisons of demographic, lifestyle, and vascular risk factors among those who experienced combined incident stroke and heart failure versus those who did not experience any of these outcomes were performed using Student’s T-test for continuous parametric variables and Fisher’s exact tests for discrete variables. A multivariate Cox Hazards Proportion regression analysis was fitted to identify factors independently associated with the risk of incident stroke or heart failure (as a combined outcome measure, and then separate outcome measures). Independent variables evaluated included age (categorized as continuous per 10-year rise), sex, WHO clinical stage at diagnosis, current CD4 T-cell count, viral load (categorized as <20, 20–1000 or >1000 copies/ml), history of hypertension, diabetes mellitus, elevated total cholesterol, use of protease inhibitor, common carotid artery intimal media thickness, carotid bulb IMT, and internal carotid artery IMT. Patients were censored either the date of stroke or heart failure, at the last visit for those who died, were lost to follow-up, and at end of study follow-up for the remainder. Bivariate analyses carried out to identify predictors to include in the final multivariate model were set at a liberal \( p \)-value of <.10. In all analyses, two-tailed \( p \)-values <.05 were considered statistically significant. Model diagnostics and fit were assessed using residual plots analysis and visual inspection for collinearity of variables in the Cox models. Statistical analysis was performed using GraphPad Prism version 7 and SPSS version 21.

3 | RESULTS

We enrolled 261 PLWH who had been on cART for at least 12 months. We excluded six participants who had already previous diagnosis of stroke (n = 5) and heart failure, leaving 255 participants for the present analysis.

3.1 | Incidence rates of stroke or heart failure

The 255 participants contributed 2940 months (245 years) of follow-up data with mean follow-up duration of 11.5 months. There were five participants who did not complete month 12 follow-up. There were three cases of incident stroke giving an incidence rate of 12.24 per 1000 person-years of follow-up (95% CI: 3.13–33.33). For heart failure, there were two events with an incidence rate of 8.16 (95%CI: 1.37–26.97) PYFU. The combined event rate was 20.41 (95% CI: 7.48–45.24) PYFU. There were no STEMI on NSTEMI recorded.

3.2 | Clinical and demographic features of participants with combined incident stroke or heart failure

The demographic and clinical features are compared in Table 1. The mean age of those with the combined CVD outcome of 50.2 ± 9.6 years was non-significantly higher than 46.1 ± 9.1 years among those with no such outcomes. There were no differences between the two groups with respect to WHO clinical stage, viral load at baseline, or combination antiretroviral therapy. Those with CVD events, however, had significantly lower mean CD4 T-cell count at 270.2 cells/mm\(^3\) compared with 649.4 cells/mm\(^3\) among those with CVD events. Those with CVD events were more likely to be hypertensive (60% versus 16%) than those without. Lipid panel, renal function indices, body mass index, and waist-to-hip ratios were comparable between the two groups. The mean intimal media thickness of the common carotid artery and carotid bulb was significantly higher among those with CVD outcomes than those without (Table 1).

3.3 | Factors associated with incident stroke or heart failure

In unadjusted analysis, CD4 T-cell count, being hypertensive, common carotid artery IMT, and carotid bulb IMT were associated with the combined outcome of stroke or heart failure. In adjusted analysis presented as adjusted hazards ratio, aHR (95% CI), two factors were independently associated with the combined outcome (Table 2). Being hypertensive was associated with aHR of 8.61 (1.32–56.04) of the combined outcome while higher CD4 count was protective against the outcome with aHR of 0.56 (0.35–0.88). In a sensitivity analysis where diastolic blood pressure was included in the model instead of hypertensive status, the adjusted HR of diastolic BP for the combined outcome was 1.64 (95% CI: 0.93–2.88), \( p = .08 \).

A sub-analysis to assess factors associated with incident stroke is presented in Table 3 and for incident heart failure in Table 4. For stroke occurrence, carotid bulb intimal media thickness was independently associated with aHR of 12.23 (1.28–117.07). For heart failure, there were no independent predictors although common carotid artery IMT and internal carotid IMT were associated with this outcome in unadjusted analysis.

4 | DISCUSSION

The combined incidence rate of stroke and heart failure among PLWH established on cART in this sample of Ghanaians is 20.41
## Table 1: Comparison of baseline characteristics of PLWH who experienced either incident stroke or heart failure

|                                    | Incident stroke/heart failure (n = 5) | No incident stroke/heart failure (n = 250) | \( p \)-value |
|------------------------------------|--------------------------------------|-------------------------------------------|---------------|
| **Age, mean ± SD**                 | 50.2 ± 9.6                           | 46.1 ± 9.1                                 | .32           |
| **Male sex, n (%)**                | 2 (40.0)                             | 42 (16.8)                                  | .17           |
| **Location of dwelling**           |                                      |                                           |               |
| Urban                              | 5 (100.0)                            | 170 (68.0)                                 | .31           |
| Semi-urban                         | 0 (0.0)                              | 64 (25.6)                                  |               |
| Rural                              | 0 (0.0)                              | 16 (6.4)                                   |               |
| **Time since HIV diagnosis (years), mean ± SD** | 11.0 ± 9.6                           | 8.5 ± 4.2                                  | .20           |
| **WHO stage**                      |                                      |                                           |               |
| 1                                  | 0 (0.0)                              | 78 (32.0)                                  | .21           |
| 2                                  | 1 (20.0)                             | 53 (21.7)                                  |               |
| 3                                  | 4 (80.0)                             | 90 (36.9)                                  |               |
| 4                                  | 0 (0.0)                              | 23 (9.4)                                   |               |
| **Current CD4 count, each 100 cells rise** | 270.2 ± 167.8                      | 649.4 ± 329.5                             | .01           |
| **Current viral load**             |                                      |                                           |               |
| <20 copies                         | 3 (60.0)                             | 166 (68.0)                                 | .92           |
| 20–1000 copies                     | 1 (20.0)                             | 35 (14.3)                                  |               |
| >1000 copies                       | 1 (20.0)                             | 43 (17.7)                                  |               |
| **Log viral load mean ± SD**       | 2.2 ± 1.9                            | 2.0 ± 1.4                                  | .74           |
| **Nucleos(t)ide backbone**         |                                      |                                           |               |
| AZT + 3TC/FTC                      | 3 (60.0)                             | 137 (55.9)                                 | .99           |
| TDF + 3TC/FTC                      | 2 (40.0)                             | 106 (43.3)                                 |               |
| D4T + 3TC                          | 0 (0.0)                              | 1 (0.4)                                    |               |
| ABC + 3TC                          | 0 (0.0)                              | 1 (0.4)                                    |               |
| **Third agent**                    |                                      |                                           |               |
| EFV or NVP                          | 4 (80.0)                             | 229 (93.5)                                 | .24           |
| PI/r                               | 1 (20.0)                             | 16 (6.5)                                   |               |
| **Current/previous cigarette smoking** | 1 (20.0)                             | 18 (7.2)                                   | .28           |
| **Alcohol use**                    |                                      |                                           |               |
| Current                            | 1 (20.0)                             | 17 (6.9)                                   | .51           |
| Previous                           | 2 (40.0)                             | 101 (40.7)                                 |               |
| Never                              | 2 (40.0)                             | 130 (52.4)                                 |               |
| **Known hypertensive**             | 3 (60.0)                             | 40 (16.0)                                  | .009          |
| **Systolic BP (mmHg), mean ± SD**  | 144.2 ± 33.2                         | 126.8 ± 22.4                               | .09           |
| **Diastolic BP (mmHg), mean ± SD** | 93.8 ± 22.6                          | 79.0 ± 13.2                                | .02           |
| **Known diabetic**                 | 0 (0.0)                              | 5 (2.0)                                    | .75           |
| **Hemoglobin A1c, mean ± SD**      | 5.4 ± 0.4                            | 5.3 ± 0.9                                  | .65           |
| **Total cholesterol, mean ± SD**   | 5.1 ± 0.7                            | 5.3 ± 1.2                                  | .68           |
| **LDL cholesterol, mean ± SD**     | 3.2 ± 0.6                            | 3.2 ± 1.0                                  | .99           |
| **HDL cholesterol, mean ± SD**     | 1.3 ± 0.1                            | 1.5 ± 0.4                                  | .34           |
| **Triglyceride, mean ± SD**        | 1.2 ± 0.3                            | 1.4 ± 0.9                                  | .72           |
| **Estimated glomerular filtration rate, mean ± SD** | 87.6 ± 2.6                           | 84.7 ± 11.1                                | .56           |
| **Body mass index, mean ± SD**     | 28.9 ± 7.5                           | 27.1 ± 5.7                                 | .50           |
| **Waist-to-hip ratio, mean ± SD**  | 0.86 ± 0.12                          | 0.88 ± 0.08                                | .47           |
| **Physical inactivity, n (%)**     | 3 (60.0)                             | 155 (62.0)                                 | .93           |

(Continues)
(95% CI: 7.48–45.24) per 1000 person-years. This incidence rate is partitioned into 12.24 (3.13–33.33) per 1000 person-years for stroke and 8.16 (95% CI: 1.37–26.97) per 1000 person-years for heart failure with no documented acute coronary event during follow-up. The crude incidence rate recorded in the present study is about 3x higher than the global estimate of 6.18 (95% CI: 4.58–8.34) per 1000 person-years for myocardial infarction and 1.79 (1.32–24.30) per 1000 person-years for stroke. There is, however, an appreciable overlap in the confidence intervals of the incidence rates in our study and that from the global estimate. The absence of acute coronary events in our study may be due to the overall mean young age of 46 years. The global estimate also did not include heart failure as an outcome measure.

Two factors were independently predictive of the occurrence of stroke or heart failure. Of foremost importance, we identified a potent association between prior diagnosis of hypertension and CVD outcomes. We have previously reported a high hypertension prevalence of 37% among PLWH on cART in Ghana. People living with HIV with hypertension in this study had an eightfold higher risk of incident CVD than those without hypertension. This risk was largely observed for stroke occurrence where hypertension was associated with nearly 11-fold higher hazards than non-hypertensive PLWH. These findings resonate with epidemiological data from West Africa where the population attributable risk of hypertension for stroke occurrence is 90.8% (95% CI: 87.9–93.7%), an indication of the pervasive contribution of hypertension to CVD incidence in the region.

Furthermore, we observed that a lower CD4 T-cell count is associated with a higher relative risk of experiencing a stroke or heart failure. Depletion of CD4 T-cells which occurs through the gut mucosa among PLWH is linked to higher risk of atherosclerotic CVD events such as MI, strokes, and peripheral vascular disease via a cascade of chronic immune activation, inflammation, and alterations in cholesterol metabolism with atherogenic lipid profiles. Furthermore,
the HIV virus itself may be implicated in cardiac failure by direct infection of cardiac myocytes. 

While some cross-sectional and few prospective studies have demonstrated associations between HIV infection, its treatment, and carotid atherosclerosis, very few have found associations with incident CVD events. Presently, the association between markers of carotid artery atherosclerosis and combined CVD outcomes of stroke and heart failure was attenuated into non-significance upon adjustment for confounders. Nonetheless, we noted that carotid bulb intimal media thickness was independently associated with stroke occurrence in our population. The one previous US study which reported associations between carotid atherosclerosis and atherosclerotic CVD found that incidental carotid plaques detected on CT scan were associated with a fourfold increased risk of stroke specifically among PLWH. In our study, carotid bulb intimal media thickness was associated with a 12-fold increased risk of stroke for a millimeter rise in carotid IMT after adjusting for hypertension in the model.

The implications of our study findings are that cardiovascular events are more common among a female-dominated and younger population of PLWH than perhaps appreciated by clinicians and policy makers. Attention to the detection and control of hypertension among PLWH is paramount in mitigating this risk. There are indications from this study and our previous report that carotid atherosclerosis is rampant in the HIV population but not a part of routine workup for PLWH in our settings. Therefore, in addition to hypertension control, implementation of interventions to reduce atherosclerotic risk such as institution of statin therapy as well as non-pharmacological therapies such as physical activity, health eating, and cigarette cessation are urgent priorities as PLWH live longer on cART.

Our study has a number of limitations. Similar to the meta-analytic data, we relied on physician diagnosis or the International Classification of Diseases coding system to define cardiovascular disease. There was no funding for diagnostic workup of study participants using neuroimaging to confirm and type clinically diagnosed strokes. However, specialists at the HIV clinic (BN), cardiologist (LTA), and neurologist (FSS) supervised the assessment and adjudication of clinical events. Because this is a single-center study conducted in a tertiary medical facility, the findings are not generalizable to a wider PLWH population who receive care in primary health centers and community health posts in Africa. However, the prospective study design is a strength, and the follow-up rate over 12 months of over 95% completion enabled us to rigorously assess clinical outcomes of interest.

### Tables

#### Table 3: Predictors of incident stroke among PLWH in Ghana

| Predictor                                         | Unadjusted HR (95% CI) | p-value | Adjusted HR (95% CI) | p-value |
|---------------------------------------------------|------------------------|---------|----------------------|---------|
| Age, each 10-year rise                            | 1.18 (0.36–3.85)       | .79     | -                    | -       |
| Male sex                                          | 9.79 (0.89–107.96)     | .06     | Not included         | -       |
| CD4 count/100 rise                                | 0.60 (0.35–1.04)       | .07     | Not included         | -       |
| Hypertensive                                      | 10.28 (0.93–113.37)    | .06     | 11.31 (0.88–144.80)  | .06     |
| Diabetes                                          | 0.00 (0.00–4.39)       | .97     | -                    | -       |
| Hypercholesterolemia                              | 1.85 (0.17–20.43)      | .61     | -                    | -       |
| Use of protease inhibitor                         | 6.96 (0.63–76.76)      | .11     | -                    | -       |
| Common carotid artery intimal media thickness (mm)| 2.00 (0.00–1770.81)    | .84     | -                    | -       |
| Carotid bulb intimal media thickness (mm)         | 8.10 (1.32–49.59)      | .02     | 12.23 (1.28–117.07)  | .03     |
| Internal carotid artery intimal media thickness (mm)| 0.44 (0.00–188.02)    | .79     | -                    | -       |

#### Table 4: Predictors of incident heart failure among PLWH in Ghana

| Predictor                                         | Unadjusted HR (95% CI) | p-value | Adjusted HR (95% CI) | p-value |
|---------------------------------------------------|------------------------|---------|----------------------|---------|
| Age, each 10-year rise                            | 2.17 (0.58–8.17)       | .25     | -                    | -       |
| Male sex                                          | 0.00 (0.00–8.52)       | .95     | -                    | -       |
| CD4 count/100 rise                                | 0.54 (0.26–1.13)       | .10     | -                    | -       |
| Hypertensive                                      | 4.99 (0.31–79.77)      | .26     | -                    | -       |
| Diabetes                                          | 0.00 (0.00–7.14)       | .97     | -                    | -       |
| Hypercholesterolemia                              | 0.00 (0.00–1.82)       | .95     | -                    | -       |
| Use of protease inhibitor                         | 0.00 (0.00–2.54)       | .96     | -                    | -       |
| Common Carotid artery intimal media thickness (mm)| 4.45 (1.41–6635.11)    | .008    | 1.91 (0.00–10.87)    | .13     |
| Carotid bulb intimal media thickness (mm)         | 4.87 (0.27–88.38)      | .28     | -                    | -       |
| Internal carotid artery intimal media thickness (mm)| 5.00 (4.87–5144.29)   | .02     | 3.79 (0.00–9584.71)  | .74     |
In conclusion, PLWH on long-term cART in this Ghanaian sample have higher rates of clinically adjudicated cardiovascular diseases driven by uncontrolled hypertension and persisting immunosuppression. Integration of CVD care into routine HIV management may help alleviate this untoward confluence of rising CVDs in PLWH.

ACKNOWLEDGMENT
We are grateful for support by study nurses (Rose Appiah, Hajia Yussif, Abigail Ameyaw, Ebenezer Agyeman and Samuel Amonoo) at the Komfo Anokye Teaching Hospital, and Research Assistants (Shadrack Asibey, Kwaku Boadu, and Evans Owusu).

CONFLICT OF INTEREST
All authors have no conflicts to declare.

AUTHOR CONTRIBUTIONS
Fred Stephen Sarfo and Bruce Ovbiagele contributed to conceptualization, methodology, and supervision. Fred Stephen Sarfo contributed to data curation, formal analysis, project analysis, and writing—original draft. Fred Stephen Sarfo, Betty Norman, and Lambert Appiah contributed to investigation. Fred Stephen Sarfo, Betty Norman, Lambert Appiah, and Bruce Ovbiagele contributed to writing—review and editing.

ORCID
Fred Stephen Sarfo https://orcid.org/0000-0001-7274-5093

REFERENCES
1. Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med. 2012;13:453-468.
2. Shah ASV, Stelzle D, Lee KK, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV. Circulation. 2018;138:1100-1112.
3. Neuhaus J, Angus B, Kowalska JD, et al. INSIGHT SMART and ESPRIT study groups. Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV/AIDS. 2010;24:697-706.
4. Mocroft A, Reiss P, Gasiorowski J, Ledergerber B, Kowalska J, Chiesi A, et al. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr. 2010;55:262-270.
5. Antiretroviral therapy cohort collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis. 2010;50:1387-1396.
6. Subramanian S, Tawakol A, Burdo TH, et al. Arterial inflammation in patients with HIV. JAMA. 2012;308:379-386.
7. Grunfeld C, Pang M, Doerrter W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74:1045-1052.
8. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48-62.
9. Roth GA, Huffman MD, Moran AE, et al. Global and regional patterns in cardiovascular mortality from 1990 to 2013. Circulation. 2015;132:1667-1678.
10. Mensah GA, Roth GA, Sampson UK, et al. Mortality from cardiovascular diseases in sub-Saharan Africa, 1990-2013: a systematic analysis of data from the global burden of disease study 2013. Cardiovasc J Afr. 2015;26(2 suppl 1):S6-S10.
11. Cois A, Day C. Obesity trends and risk factors in the South African adult population. BMC Obes. 2015;2:42.
12. Keates AK, Mocumbi AO, Ntsekhe M, Sliwa K, Stewart S. Cardiovascular disease in Africa: epidemiological profile and challenges. Nat Rev Cardiol. 2017;14(5):273-293.
13. Nashilongo MM, Singu B, Kalemeera F, et al. Assessing adherence to antihypertensive therapy in primary health care in Namibia: findings and implications. Cardiovasc Drugs Ther. 2017;31:565-578.
14. Okello S, Amir A, Bloomfield GS, et al. Prevention of cardiovascular disease among people living with HIV in sub-Saharan Africa. Prog Cardiovasc Dis. 2020;63(2):149-159.
15. Sarfo FS, Norman B, Nichols M, et al. Prevalence and incidence of pre-diabetes and diabetes mellitus among people living with HIV in Ghana: evidence from the EVERLAST Study. HIV Med. 2020;22(4):231-243.
16. Sarfo FS, Singh A, Tagge R, Mensah G, Ovbiagele B. Duration of antiretroviral therapy among people living with HIV and incidence of hypertension in Ghana. J Clin Hypertens (Greenwich). 2020;22(12):2361-2371.
17. Atakle F, Erqou S, Kaptoge S, Taye B, Echouffo-Tcheugui JB, Kengue AP. Burden of undiagnosed hypertension in sub-Saharan Africa. Hypertension. 2015;65:291-298.
18. Reiger S, Jardim TV, Abrams-Gessel S, et al. Awareness, treatment and control of dyslipidemia in rural South Africa: the HAALSI (Health and Aging in Africa: a longitudinal study of an INDEPTH community in South Africa) study. PLoS One. 2017;12(10):e0187347.
19. So-Armah K, Benjamin LA, Bloomfield GS, et al. HIV and cardiovascular disease. Lancet HIV. 2020;7:e279-e293.
20. Sarfo FS, Nichols M, Gebregziabher M, et al. Evaluation of vascular antiretroviral therapy among people living with HIV and incidence of hypertension in Ghana. J Neurol Sci. 2019;397:103-111.
21. World Health Organization. Guidelines sub-committee. 1999 World health organization-International society of hypertension guidelines for the management of hypertension. J Hypertens. 1999;17:151-183.
22. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of high blood cholesterol in adults (Adult treatment panel). Third report of the National cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high cholesterol in adults (Adult Treatment Panel III). Circulation. 2002;106:3143-3421.
23. World Health Organization. Waist circumference and waist-hip ratio. Report of a WHO expert consultation. 2008. http://www.who.int/nutrition/publications/obesity/WHO_report_waistcircumference_and_waist_ratio/en/ (Accessed May 27, 2020).
24. American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care. 2015;40(suppl 1):S11-S24.
25. Roman MJ, Naqvi TZ, Gardin JM, et al. A report from the American society of echocardiography and the society of vascular medicine and biology. Circulation. 2015;132:1667-1678.
26. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48-62.
27. Roth GA, Huffman MD, Moran AE, et al. Global and regional patterns in cardiovascular mortality from 1990 to 2013. Circulation. 2015;132:1667-1678.
28. Mensah GA, Roth GA, Sampson UK, et al. Mortality from cardiovascular diseases in sub-Saharan Africa, 1990-2013: a systematic analysis of data from the global burden of disease study 2013. Cardiovasc J Afr. 2015;26(2 suppl 1):S6-S10.
30. Sarfo FS, Mobula LM, Plange-Rhule J, Ansong D, Ofori-Adjei D. Incident stroke among Ghanaians with hypertension and diabetes: a multicenter, prospective cohort study. J Neurol Sci. 2018;395:17-24.
31. Sarfo FS, Nichols M, Singh A, et al. Characteristics of hypertension among people living with HIV in Ghana: impact of new hypertension guideline. J Clin Hypertens (Greenwich). 2019;21(6):838-850.
32. Owolabi MO, Sarfo F, Akinyemi R, et al. Dominant modifiable risk factors for stroke in Ghana and Nigeria (SIREN): a case-control study. Lancet Glob Health. 2018;6(4):e436-e446.
33. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365-1371.
34. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289:2978-2982.
35. Benjamin LA, Allain TJ, Mzinganjira H, et al. The role of human immunodeficiency virus-associated vasculopathy in the etiology of stroke. J Infect Dis. 2017;216:545-553.
36. Grody WW, Cheng L, Lewis W. Infection of the heart by the human immunodeficiency virus. Am J Cardiol. 1990;66:203-206.
37. Grunfeld C, Delaney JA, Wanke C, et al. Preclinical atherosclerosis due to HIV infection: carotid intima-media thickness measurements from the FRAM study. AIDS. 2009;23:1841-1849.
38. Hsue PY, Hunt PW, Schnell A, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS. 2009;23:1059-1067.
39. Volpe GE, Tang AM, Polak JF, Mangili A, Skinner SC, Whane CA. Progression of carotid intima-media thickness and coronary artery calcium over 6 years in an HIV-infected cohort. J Acquir Immune Defic Syndr. 2013;64:51-57.
40. Hanna DB, Post WS, Deal JA, et al. HIV infection is associated with progression of subclinical carotid atherosclerosis. Clin Infect Dis. 2015;61(4):640-650.
41. Janjua SA, Staziaki PV, Szilveszter B, et al. Presence, characteristics and prognostic associations of carotid plaque among persons living with HIV. Circ Cardiovasc Imaging. 2017;10(10):e005777.
42. Sarfo FS, Opare-Sem O, Ageyi M, et al. Risk factors for stroke occurrence in a low HIV endemic West African country: a case-control study. J Neurol Sci. 2018;395:8-16.
43. Ayisi-Boateng NK, Mohammed A, Opoku DA, Sarfo FS. Frequency and factors associated with apparent resistant hypertension among Ghanaians in multicenter study. J Clin Hypertens. 2020;22(9):1594-1602.
44. Sarfo FS, Akassi J, Adamu S, Obese V, Agbenoriku M, Ovbiagele B. Frequency and factors linked to refractory hypertension among stroke survivors in Ghana. J Neurol Sci. 2020;415:116976.
45. Sarfo FS, Mobula L, Plange-Rhule J, Gebregziabher M, Ansong D. Longitudinal control of blood pressure among a cohort of Ghanaians with hypertension: a multicenter, hospital-based study. J Clin Hypertens. 2020;22(6):949-958.
46. Sarfo FS. Associations between hypertension knowledge, awareness, and treatment and stroke occurrence across the globe: time to act on what we know. Heart. 2021;107(4):264-265.
47. Sarfo FS, Ovbiagele B. Prevalence and predictors of statin utilization among patient populations at high vascular risk in Ghana. J Neurol Sci. 2020;414:116838.
48. Appiah LT, Sarfo FS, Huffman MD, Nguah SB, Stiles JK. Cardiovascular risk factors among Ghanaian patients with HIV: a cross-sectional study. Clin Cardiol. 2019;42(12):1195-1201.
49. Sarfo FS. Dyslipidemia among African adults. Lancet Global Health. 2018;6(9):e940-e941.

How to cite this article: Sarfo FS, Norman B, Appiah L, Ovbiagele B. Factors associated with incidence of stroke and heart failure among people living with HIV in Ghana: Evaluating Vascular Event Risk while on Long-Term Antiretroviral Suppressive Therapy (EVERLAST) Study. J Clin Hypertens. 2021;23:1252-1259. https://doi.org/10.1111/jch.14255